Details About Generic Salt ::  Modafini

Main Medicine Class:: CNS stimulant,Analeptic   

Tablets: 100 mg, 200 mg
Class: CNS stimulant/Analeptic


Drugs Class ::

 Action Wakefulness-promoting agent; however, precise mechanism(s) unknown.

Indications for Drugs ::

 Indications Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.

Drug Dose ::


ADULTS AND CHILDREN 16 YR AND OLDER: PO 200 mg/day as a single morning dose. Hepatic impairment: A dose reduction of 50% is recommended.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::


Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy in children less than 16 yr not established. Drug dependence: Because of psychoactive and euphoric effects, modafinil has potential for abuse. Hepatic impairment: Dosage reduction is recommended in patients with severe hepatic impairment.


Drug Side Effects ::

 Adverse Reactions

CV: Hypotension; hypertension; vasodilation; arrhythmia; syncope. CNS: Headache; nervousness; dizziness; depression; anxiety; cataplexy; insomnia; dyskinesia; confusion; amnesia; emotional lability. DERM: Herpes simplex; dry skin. EENT: Rhinitis; pharyngitis; amblyopia; abnormal vision. GI: Nausea; diarrhea; dry mouth; anorexia; vomiting; mouth ulcer; gingivitis; thirst. GU: Abnormal urine; urinary retention; abnormal ejaculation. HEPA: Abnormal liver function. META: Hyperglycemia; albuminuria. RESP: Lung disorder; dyspnea; asthma; epistaxis. OTHER: Paresthesia; hypertonia; ataxia; tremor; chest pain; neck pain; chills; rigid neck; fever and chills; joint disorder.

Drug Mode of Action ::  

 Action Wakefulness-promoting agent; however, precise mechanism(s) unknown.

Drug Interactions ::


Clomipramine: Plasma levels may be increased by modafinil. Cyclosporine: Blood levels may be decreased by modafinil. MAO inhibitors (eg, isocarboxazid): Use with caution. Methylphenidate: May delay the absorption of modafinil. Oral contraceptives: Efficacy may be decreased by modafinil, increasing the risk of unintended pregnancy. Phenytoin: Increased risk of phenytoin toxicity. Tricyclic antidepressants (certain TCAs [eg, clomipramine, desipramine]): Plasma levels of certain TCAs may be increased. Warfarin: Monitor prothrombin times.

Drug Assesment ::


  • Obtain patient history, including drug history and any known allergies. Note history of the following: significant manifestations of mitral valve prolapse (eg, chest pain, palpitations, dyspnea, ischemic ECG changes) with previous CNS stimulant use; recent MI; unstable angina; liver disease; psychosis; drug or stimulant abuse.
  • Monitor patient for response to therapy.
  • Administer reduced dose to patient with severe hepatic impairment.
  • Monitor blood pressure periodically in patient with history of hypertension.
  • Monitor patient for CNS, CV, GI, and general body side effects. Report to health care provider if noted and significant.
  Excitation, agitation, insomnia, slight to moderate elevations in hemodynamic parameters, anxiety, irritability, aggressiveness, confusion, nervousness, tremor, palpitations, sleep disturbances, nausea, diarrhea, decreased prothrombin time

Drug Storage/Management ::


  • Administer prescribed dose once daily.
  • Administer dose in morning to minimize sleep disturbances.
  • Administer without regard to food.
  • Store at controlled room temperature (68° to 77°F).

Drug Notes ::

 Patient/Family Education

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient to take prescribed dose once daily. Advise patient to take dose in the morning to minimize sleep disturbances.
  • Advise patient that medication should be taken as prescribed and to not stop taking or to change the dose unless advised to by the health care provider.
  • Caution patient that medication may impair ability to drive or perform other tasks requiring mental alertness and to use caution until effect of medication has been determined.
  • Advise patient or caregiver to notify health care provider if appetite loss, nervousness, or difficulty sleeping occur and are bothersome.
  • Advise patient to notify health care provider if rash, hives, or other symptoms of an allergic reaction occur, or if any unusual or unexplained symptoms are noted.
  • Advise women using hormonal contraception (eg, oral, depot, implantable) to use alternative or concomitant methods of contraception with and for 1 mo following discontinuation of therapy.
  • Advise women to inform the health care provider if becoming pregnant, planning on becoming pregnant, or breastfeeding.
  • Warn patient to not take any prescription or OTC drugs or dietary supplements without consulting health care provider.
  • Advise patient or caregiver that follow-up visits and lab tests may be necessary to monitor therapy and to be sure to keep appointments.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.


One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.